| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Prospective Study |
| Article Title |
Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ligia Yukie Sassaki, Sender J Miszputen, Roberto Luiz Kaiser Junior, Wilson R Catapani, Mauro Bafutto, António S Scotton, Cyrla Zaltman, Julio Pinheiro Baima, Hagata S Ramos, Mikaell Alexandre Gouvea Faria, Carolina D Gonçalves, Isabella Miranda Guimaraes, Cristina Flores, Heda M B S Amarante, Rodrigo Bremer Nones, José Miguel Luz Parente, Murilo Moura Lima, Júlio Maria Chebli, Maria de Lourdes Abreu Ferrari, Julia F Campos, Maria G P Sanna, Odery Ramos, Rogério Serafim Parra, Jose J R da Rocha, Omar Feres, Marley R Feitosa, Rosana Fusaro Caratin, Juliana Tosta Senra and Genoile Oliveira Santana |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Takeda Pharmaceuticals Brazil |
|
|
| Corresponding Author |
Ligia Yukie Sassaki, PhD, Doctor, Department of Internal Medicine, Botucatu Medical School at Sao Paulo State University (UNESP), Avenida Professor Mário Rubens Guimarães Montenegro, Botucatu 18618-687, São Paulo, Brazil. ligiasassaki@gmail.com |
| Key Words |
Crohn’s disease; Ulcerative colitis; Inflammatory bowel diseases; Prospective study |
| Core Tip |
This was a prospective, noninterventional study of 118 adult patients with active Crohn’s disease (CD) and 36 with active ulcerative colitis (UC). The aim was to describe the 12-mo disease evolution and treatment patterns of active moderate-to-severe inflammatory bowel disease (IBD) patients in Brazil. The median time to first mild or no activity was 319 (IQR: 239-358) d for CD and 320 (IQR: 288-358) d for UC patients. A marked proportion of active IBD patients achieved disease control within one year, which is considered a long time to achieve the goal of reducing inflammation. |
| Publish Date |
2021-06-18 05:06 |
| Citation |
Sassaki LY, Miszputen SJ, Kaiser Junior RL, Catapani WR, Bafutto M, Scotton AS, Zaltman C, Baima JP, Ramos HS, Faria MAG, Gonçalves CD, Guimaraes IM, Flores C, Amarante HMBS, Nones RB, Parente JML, Lima MM, Chebli JM, Ferrari MLA, Campos JF, Sanna MGP, Ramos O, Parra RS, da Rocha JJR, Feres O, Feitosa MR, Caratin RF, Senra J, Santana GO. Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil. World J Gastroenterol 2021; 27(23): 3396-3412 |
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i23/3396.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i23.3396 |
